Core Viewpoint - The Chinese medicine sector is experiencing significant growth, with the Zhongzheng Traditional Chinese Medicine Index and related ETFs showing strong performance, indicating a positive market sentiment towards traditional Chinese medicine companies [1][2][3]. Group 1: Market Performance - As of August 1, 2025, the Zhongzheng Traditional Chinese Medicine Index rose by 2.63%, with notable increases in constituent stocks such as Xintian Pharmaceutical (up 10.03%) and Tailong Pharmaceutical (up 10.00%) [1]. - The Zhongzheng Traditional Chinese Medicine ETF (560080) increased by 3.06%, reaching a latest price of 1.15 yuan, and has seen a cumulative increase of 2.58% over the past two weeks [1]. - The trading volume for the Zhongzheng Traditional Chinese Medicine ETF was 59.73 million yuan, with a turnover rate of 3.02% [1]. Group 2: Fund Growth - The Zhongzheng Traditional Chinese Medicine ETF experienced a significant scale increase of 57.84 million yuan over the past week, ranking first among comparable funds [2]. - The ETF's share count grew by 31.50 million shares in the same period, also placing it at the top among comparable funds [3]. Group 3: Capital Flow - The latest net capital outflow for the Zhongzheng Traditional Chinese Medicine ETF was 14.52 million yuan, but there was a net inflow of 43.60 million yuan over the last five trading days, averaging 8.72 million yuan per day [4]. - Leverage funds are increasingly investing in the ETF, with the latest margin buying amounting to 6.77 million yuan and a margin balance of 52.14 million yuan [4]. Group 4: Industry Developments - Tongrentang Group's healthcare segment "Tongrentang Medical Care" successfully listed on the Hong Kong Stock Exchange, marking its fourth company listed in Hong Kong, focusing on integrated medical services [4]. - The company aims to acquire five medical institutions and upgrade systems with the funds raised, projecting revenues between 911 million and 1.175 billion yuan from 2022 to 2024 [4]. Group 5: Regulatory Environment - A nationwide initiative is underway to regulate the pricing of traditional Chinese medicine, addressing issues of inflated prices for commonly used products [5]. - The ongoing centralized procurement of traditional Chinese medicine is expected to expand, affecting 20%-30% of the market, which may lead to increased brand concentration in the retail market [5].

Core Viewpoint - The company has decided to cancel its supervisory board and amend its articles of association to enhance its corporate governance structure, with the supervisory board's responsibilities being transferred to the audit committee of the board [1][2]. Group 1: Board Meeting Details - The 33rd meeting of the 9th Board of Directors was held on July 30, 2025, with all 9 directors present, including some attending via communication [1]. - The meeting's procedures complied with relevant laws and regulations, ensuring the legality and validity of the resolutions made [1]. Group 2: Resolutions Passed - The resolution to cancel the supervisory board and amend the articles of association was passed unanimously with 9 votes in favor, requiring further approval from the shareholders' meeting [2]. - The company also approved the revision of 22 governance documents, including the rules for shareholder meetings and board meetings, with the same unanimous voting outcome [2][3]. - The board approved the nomination of candidates for the 10th Board of Directors, including both non-independent and independent directors, with all resolutions receiving 9 votes in favor [5][6]. Group 3: Upcoming Events - The company plans to hold its third extraordinary shareholders' meeting on August 15, 2025, to review the resolutions passed by the board [6].

General Principles - The company establishes information disclosure regulations to protect investors' rights and comply with relevant laws and regulations [1][2] - Information disclosure is defined as the timely release of information that may significantly impact the company's securities prices [1][2] Basic Principles of Information Disclosure - Information disclosure is a continuous responsibility of the company, requiring timely, truthful, accurate, and complete information [2][3] - Information must be disclosed simultaneously to all investors, and insider information must not be leaked before official disclosure [2][3] Content and Standards of Information Disclosure - The company must disclose periodic reports, temporary reports, and other relevant documents as required by law [5][6] - Annual reports must be disclosed within four months after the fiscal year-end, and interim reports within two months after the first half of the fiscal year [6][7] Procedures for Information Disclosure - The company must follow specific procedures for preparing, reviewing, and disclosing periodic reports, ensuring that all necessary approvals are obtained [12][13] - Major events that could significantly affect the company's securities must be disclosed immediately [9][10] Responsibilities of Information Disclosure Personnel - The board secretary is responsible for managing information disclosure and ensuring compliance with regulations [14][15] - Directors and senior management must cooperate with the board secretary and ensure timely and accurate information reporting [16][17] Confidentiality Measures - Company personnel with access to undisclosed information must maintain confidentiality and not misuse insider information [19][20] - The company should implement necessary measures to limit the number of individuals who have access to sensitive information [19][20] Accountability and Penalties - Directors and senior management are accountable for the truthfulness, accuracy, completeness, and timeliness of disclosed information [21][22] - Violations of disclosure regulations may result in penalties imposed by the board of directors based on the severity of the breach [21][22]

Core Viewpoint - The document outlines the establishment of a compensation and assessment management system for the board of directors and senior management of Henan Tailong Pharmaceutical Co., Ltd, aiming to enhance corporate governance and comply with relevant laws and regulations [1][2]. Group 1: Committee Structure - The Compensation and Assessment Committee is a specialized committee under the board of directors, responsible for formulating assessment standards and compensation policies for directors and senior management [1]. - The committee consists of three directors, with a majority being independent directors, and is chaired by an independent director [4][5]. - The term of the committee aligns with that of the board, and members can be re-elected upon term expiration [4] Group 2: Responsibilities and Authority - The main responsibilities of the committee include developing assessment standards, reviewing compensation policies, and making recommendations to the board on various matters [3]. - Compensation plans for directors must be approved by the board and submitted for shareholder approval, while plans for senior management require board approval [3][5]. - The board must document and disclose any reasons for not adopting the committee's recommendations [3][5]. Group 3: Meeting Procedures - The committee is required to hold at least one regular meeting annually, with provisions for additional meetings as necessary [4]. - Meetings can be conducted in person or via teleconference, ensuring all members can communicate effectively [4][5]. - A quorum of two-thirds of the committee members is required for meetings, and decisions must be made by a majority vote [5][6]. Group 4: Documentation and Confidentiality - Meeting records must be created and signed by attendees, with a retention period of no less than ten years [5]. - All participants in the meetings are bound by confidentiality regarding the discussed matters [5][6].

Core Points - The document outlines the governance structure and operational guidelines for Henan Tailong Pharmaceutical Co., Ltd, focusing on the roles and responsibilities of the general manager and other key management positions [1][2][3]. Group 1: General Manager's Role - The company appoints one general manager, who is responsible for the overall management and implementation of the board's resolutions [1]. - The general manager has a three-year term and can be reappointed [1]. - Responsibilities include organizing production management, implementing annual plans, and proposing internal management structures [1][3]. Group 2: Deputy General Manager's Responsibilities - The deputy general manager is accountable for business management within their scope and must report regularly to the general manager [2]. - They are responsible for executing tasks assigned by the general manager and the board [2]. Group 3: Financial Officer's Duties - The financial officer oversees the financial department and is responsible for internal controls and audits [2]. - They must review financial reports and ensure compliance with accounting standards [2]. Group 4: Board Secretary's Functions - The board secretary is tasked with preparing and managing shareholder and board meetings, as well as handling information disclosure [2]. Group 5: General Manager's Responsibilities - The general manager must maintain shareholder interests and ensure effective implementation of the board's plans [3]. - They are also responsible for enhancing management levels and economic efficiency [3]. - Regular reporting to the board and adherence to company regulations are mandatory [4]. Group 6: Meeting Procedures - The general manager's office meetings are held weekly to discuss significant operational matters [4]. - Decisions made in these meetings must be executed by relevant departments and reported back to the general manager [4]. Group 7: Miscellaneous Provisions - The document stipulates that any unresolved issues will be governed by relevant laws and the company's articles of association [5]. - The guidelines take effect upon approval by the board [5].

第四条 独立董事应当独立履行职责，不受公司及公司主要股东、 实际控制人以及其他与公司存在利害关系的组织或者个人的影响。公 司应当为独立董事依法履职提供必要保障。 第五条 公司独立董事占董事会成员的比例不得低于三分之一， 且至少包括一名会计专业人士。公司董事会审计委员会中独立董事 应当过半数，并由独立董事中会计专业人士担任召集人；提名委员 会、薪酬与考核委员会中独立董事应当过半数并担任召集人。 河南太龙药业股份有限公司 第一章 总 则 第一条 河南太龙药业股份有限公司（以下简称"公司"）为进 一步完善法人治理结构，促进公司持续规范发展，为独立董事创造良 好的工作环境，充分发挥独立董事在公司治理中的作用，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司独立董事 管理办法》《上海证券交易所上市公司自律监管指引第1号——规范 运作》等有关法律法规以及《河南太龙药业股份有限公司章程》（以 下简称"《公司章程》"）的规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 公司及公司主要股东、实际控制人不存在直接或者间接利害关系，或 者其他可能影响其进行独立客观判断关系的董事。 第三条 ...

河南太龙药业股份有限公司 第一章 总 则 第一条 河南太龙药业股份有限公司（以下简称"公司"）为进 一步完善法人治理结构，充分发挥独立董事参与决策、监督制衡、专 业咨询的作用，维护公司整体利益，保护中小股东合法权益，根据中 国证券监督管理委员会《上市公司独立董事管理办法》、上海证券交 易所《上市公司自律监管指引第1号——规范运作》以及《河南太龙 药业股份有限公司章程》（以下简称"《公司章程》"）《独立董事 工作制度》等相关规定，特制定本细则。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 公司及其主要股东、实际控制人不存在直接或间接利害关系，或者其 他可能影响其进行独立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当 认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用， 维护公司整体利益，保护中小股东合法权益。 第四条 独立董事专门会议是指全部由公司独立董事参加的会 议。 第二章 职责权限 第五条 下列事项应当经公司独立董事专门会议审议，并经全体 独立董事过半数同意后，提交董事会审议： （二）向董事会提议召开临时股东会； （三）提议召开董事会会议。 独立董事 ...

General Provisions - The company is established as a joint-stock limited company in accordance with the Company Law and other relevant regulations [2] - The registered capital of the company is RMB 573.886283 million, and the paid-in capital is also RMB 573.886283 million [2][3] - The company is intended to exist permanently as a joint-stock limited company [3] Business Objectives and Scope - The company's mission is to safeguard health, with quality as the foundation, market orientation, and a focus on efficiency, aiming for high-quality development and ensuring shareholder rights [5] - The business scope includes the production and sale of pharmaceuticals, health foods, pre-packaged foods, medicinal plants, medical devices, sanitary products, cosmetics, consulting services, and technology services [5] Party Organization - The company has established a party organization that plays a leading and political core role, ensuring the implementation of national policies and strategies [4][6] Share Issuance - The company's shares are issued in the form of stocks, adhering to principles of openness, fairness, and justice [8] - The total number of shares issued by the company is 573.886283 million, all of which are ordinary shares [7] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, supervision of company operations, and access to company documents [11][36] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not abuse their rights to harm the company or other shareholders [18][42] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with the annual meeting occurring within six months after the end of the previous fiscal year [50] - Shareholder meetings require a quorum and must follow specific procedures for proposals, notifications, and voting [66][82] Decision-Making and Voting - Ordinary resolutions require a simple majority, while special resolutions require two-thirds of the voting rights present [82][84] - The company must disclose the results of votes affecting minority investors separately [85]

河南太龙药业股份有限公司 第一章 总则 第一条 为了提高河南太龙药业股份有限公司(以下简称"公司") 的规范运作水平增强信息披露的真实性、准确性、完整性和及时性, 提高年报信息披露的质量和透明度，根据《中华人民共和国公司法》 （以下简称"《公司法》"）《中华人民共和国证券法》（以下简称 "《证券法》"）《上市公司信息披露管理办法》《上海证券交易所 股票上市规则》《上海证券交易所上市公司规范运作指引》等有关法 律法规，及《公司章程》、《信息披露事务管理制度》等规定，结合 公司实际情况，制定本制度。 第二条 本制度所指责任追究制度是指年报信息披露工作中有关 人员不履行或者不正确履行职责、义务或其他个人原因，对公司造成 重大经济损失或造成不良社会影响时的追究与处理制度。 第三条 本制度适用于公司董事、高级管理人员、各子公司负责 人、控股股东及实际控制人以及与年报信息披露工作有关的其他人员。 第四条 实行责任追究制度，应遵循以下原则：实事求是、客观 公正、有错必究；过错与责任相适应；责任与权利对等原则。 第五条 公司证券部门在董事会秘书领导下负责收集、汇总与追 究责任有关的资料，按制度规定提出相关处理方案，逐级上报公 ...

Core Points - The document outlines the information disclosure management system for the company, aiming to protect the rights of investors, creditors, and other stakeholders, in accordance with relevant laws and regulations [1][2] - It defines "non-financial enterprise debt financing instruments" as securities issued by the company in the interbank bond market, which require timely and accurate information disclosure [1][2] - The company is obligated to disclose significant information that may impact its debt repayment ability or investor rights during the issuance and duration of the debt financing instruments [1][2] Information Disclosure Requirements - The company must disclose audited financial reports for the last three years and the most recent accounting statements before issuing debt financing instruments [6] - A prominent notice must be included in the offering document stating that registration does not imply any evaluation of investment value or risk by the association [7] - The company is required to disclose the issuance results, including actual issuance scale, term, and price, no later than the first trading day of the debt financing instruments [8] Ongoing Disclosure Obligations - During the duration of the debt financing instruments, the company must disclose periodic reports, including annual reports within four months after the fiscal year-end, semi-annual reports within two months after the first half of the fiscal year, and quarterly financial statements within one month after the end of each quarter [10] - The company must disclose any significant events that may affect its debt repayment ability or investor rights in a timely manner, including changes in management, financial audits, or significant losses [12][13] Management of Disclosure - The financial department is responsible for managing information disclosure, ensuring compliance with relevant laws and regulations [11] - The board of directors must implement necessary measures to control the dissemination of undisclosed information [12] - Any violations of the disclosure rules will lead to internal penalties for responsible individuals and potential legal consequences [13]